Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Sunshine Biopharma (SBFM) Long-Term Debt Repayments (2017 - 2022)

Sunshine Biopharma filings provide 7 years of Long-Term Debt Repayments readings, the most recent being $1.9 million for Q1 2022.

  • On a quarterly basis, Long-Term Debt Repayments rose 3858.33% to $1.9 million in Q1 2022 year-over-year; TTM through Dec 2022 was $1.9 million, a 299.73% increase, with the full-year FY2022 number at $1.9 million, up 299.73% from a year prior.
  • Long-Term Debt Repayments hit $1.9 million in Q1 2022 for Sunshine Biopharma, up from $23664.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $1.9 million in Q1 2022 to a low of -$767.0 in Q2 2019.
  • Median Long-Term Debt Repayments over the past 5 years was $53767.0 (2019), compared with a mean of $248100.8.
  • Biggest five-year swings in Long-Term Debt Repayments: tumbled 105.02% in 2019 and later surged 3858.33% in 2022.
  • Sunshine Biopharma's Long-Term Debt Repayments stood at $48000.0 in 2018, then crashed by 101.6% to -$767.0 in 2019, then surged by 13998.31% to $106600.0 in 2020, then crashed by 77.8% to $23664.0 in 2021, then skyrocketed by 7929.07% to $1.9 million in 2022.
  • The last three reported values for Long-Term Debt Repayments were $1.9 million (Q1 2022), $23664.0 (Q4 2021), and $124309.0 (Q3 2021) per Business Quant data.